A Lack of Standardization in Toxicity Reporting Leaves the Field Open to Misinformation
Emily A. Simons, MD, MPH+more
With many new lung cancer treatments approved through accelerated tracks based on early-phase (I/II) trial data, we have become increasingly aware of the lack of standards for disclosing toxicities when […] Read more
High Risk of Thromboembolic Events in Patients With NSCLC With ALK/ROS1 Fusions
Chuchu Shao, MD+more
The relationship between cancer and thromboembolic events as been widely studied since 1895. As we know, venous thromboembolism (VTE) is a well-recognized complication of malignancy, including pulmonary embolism (PE), deep-vein […] Read more
Physician's Twitter Campaign Boosts UK Quit Smoking Efforts
Conni Bergmann KouryMore than 1 million smokers—and counting—have #QuitforCOVID. Read more
Remotely Monitoring Patients With Cancer Has Applicability During COVID-19 Pandemic and Beyond
Conni Bergmann KouryThe pandemic underscores unmet needs in critical care management and presents an opportunity for learning from patients with cancer. Read more
Decade in Review: Changes in Smoking Behaviors Are Altering the Clinical Picture of Lung Cancer
Kara Nyberg, PhDLung cancer still holds the top position worldwide in terms of the number of new cases and deaths each year, which in 2018 reached 2.1 million and 1.8 million, respectively.1 Given that roughly 85% […] Read more
The Current Role of Combination Maintenance Therapy (Pemetrexed and Bevacizumab) in the Era of Immunotherapy
Yoshimasa Shiraishi+more
Immune checkpoint inhibitors (ICIs) and molecular targeting drugs used against oncogenic drivers, such as EGFR or ALK, have dramatically changed the treatment of NSCLC.1-6 However, treatment options after those drugs […] Read more
Questions Remain Following Long-Term Results of the Phase II SABR-COMET Trial
Ricardo Sales dos Santos, MD, PhDIn Response To: Palma DA, Olson R, Harrow, S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. […] Read more
Experts Discuss Benefits, Challenges with Lung Cancer Screening: A Pro/Con
Ugo Pastorino, MD+more
Using LDCT to Boost Lung Cancer Prevention Strategies: A Pro/Con By Ugo Pastorino, MD Now we know from robust randomized trials that systematic screening with low-dose computed tomography (LDCT) of […] Read more
Lung Cancer Health Care Delivery, Community Building, and Research: Are They Truly Inclusive?
Jill Feldman, MA+more
Lung cancer was first identified as a distinct disease in 1761.1 Since this discovery, we have come a long way—both in terms of progress towards understanding the heterogeneous biology of […] Read more